NCT01422772View on ClinicalTrials.gov

Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

August 31, 2014

Conditions
Ischemic Heart Disease
Interventions
BIOLOGICAL

VM202-0.5 mg

0.5 mg intramyocardial injection

BIOLOGICAL

VM202-1.0 mg

1 mg intramyocardial injection

BIOLOGICAL

VM202-2.0 mg

2 mg intramyocardial injection

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Helixmith Co., Ltd.

INDUSTRY

NCT01422772 - Safety Study of Gene Therapy for Ischemic Heart Disease in Korea | Biotech Hunter | Biotech Hunter